Polymorphisms of TAP1 and TAP2 genes in Graves' disease

被引:41
|
作者
Rau, H
Nicolay, A
Usadel, KH
Finke, R
Donner, H
Walfish, PG
Badenhoop, K
机构
[1] UNIV FRANKFURT KLINIKUM,ZENTRUM INNEREN MED,MED KLIN 1,DEPT MED 1,D-60590 FRANKFURT,GERMANY
[2] BENJAMIN FRANKLYN UNIV HOSP,DEPT MED,DIV ENDOCRINE,BERLIN,GERMANY
[3] UNIV TORONTO,SCH MED,MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV ENDOCRINOL & METAB,TORONTO,ON M5S 1A1,CANADA
[4] UNIV TORONTO,SCH MED,MT SINAI HOSP,SAMUEL LUNENFELD RES INST,HEAD & NECK ONCOL PROGRAM,TORONTO,ON M5S 1A1,CANADA
来源
TISSUE ANTIGENS | 1997年 / 49卷 / 01期
关键词
autoimmunity; Graves' disease; HLA; MHC; TAP;
D O I
10.1111/j.1399-0039.1997.tb02704.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Graves' disease is an autoimmune disorder in which HLA DQA1*0501 and DQB1*0201 confer predisposition. The genes for transporters associated with antigen processing (TAP1 and TAP2) locate near to HLA DQ coding regions and display only a limited degree of polymorphism. Since polymorphisms of TAP might influence susceptibility to Graves' disease by a possibly different selection of antigenic peptides, we investigated sequence variants of TAP1 and TAP2 genes in 235 patients with Graves' disease and 218 random healthy controls by polymerase chain reaction (PCR) followed by sequence specific oligonucleotide analysis (SSO), single strand conformational polymorphism (SSCP) analysis and amplification refractory mutation system (ARMS). TAP1*0301 (Val-333/Asp-637: 71% vs. 55% in controls, p<0.008, RR=2.05) and TAP2*0101 (Val-379/Ala-565/Thr-665/stop-687: 83% vs. 69% in controls, p<0.03, RR=2.20) showed a positive association with Graves' disease whereas TAP1*0401 a negative (Ile-333/Gly-637: 4% vs. 13% in controls, p<0.01, RR=0.25). After selection of patients and controls for HLA DQA1*0501 a similar association was found for TAP1*0301 (72% vs. 50% in controls, p<0.02, RR=2.63) and TAP1*0401 (4% vs. 16% in controls, p<0.04, RR=0.22), when matching for HLA DQB1*0201 as well as for TAP1*0401 (3% vs. 16% in controls, p<0.05, RR=0.18). Our findings indicate that the positive association of TAP1*0301 and the negative of TAP1*0401 with Graves' disease cannot only be explained by linkage disequilibrium between TAP alleles and HLA DQ. Therefore, these TAP alleles contribute to genetic susceptibility in Graves' disease as additional permissive and protective factors.
引用
收藏
页码:16 / 22
页数:7
相关论文
共 50 条
  • [21] Association of TAP1 and TAP2 with systemic sclerosis in Japanese
    Takeuchi, F
    Kuwata, S
    Nakano, K
    Nabeta, H
    Hong, GH
    Shibata, Y
    Tanimoto, K
    Ito, K
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1996, 14 (05) : 513 - 521
  • [22] RESTORATION OF MUTANT PHENOTYPES BY TRANSFECTION OF TAP1 AND TAP2
    KELLY, A
    TROWSDALE, J
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 57 - 57
  • [23] Mouse strains with point mutations in TAP1 and TAP2
    Theodoratos, Angelo
    Whittle, Belinda
    Enders, Anselm
    Tscharke, David C.
    Roots, Carla M.
    Goodnow, Christopher C.
    Fahrer, Aude M.
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 2010, 88 (01): : 72 - 78
  • [24] TAP1 and TAP2 epitopes in HIV-1 disease progression.
    Louie, LG
    Gittens, T
    Klitz, W
    [J]. HUMAN IMMUNOLOGY, 1996, 49 : 25 - 25
  • [25] ROLE OF TAP1 AND TAP2 POLYMORPHISMS IN AMOXICILLIN-CLAVULANATE HEPATOTOXICITY (AC DILI)
    Medina Caliz, I
    Stephens, C.
    Garcia, E. M.
    Garcia-Cortes, M.
    Moreno, I
    Hallal, H.
    Soriano, G.
    Fernandez, M. C.
    Ruiz-Cabello, F.
    Andrade, R. J.
    Lucena, M., I
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 53 - 53
  • [26] TAP1 and TAP2 polymorphisms analysis in northwestern Colombian patients with systemic lupus erythematosus
    Correa, PA
    Molina, JF
    Pinto, LF
    Arcos-Burgos, M
    Herrera, M
    Anaya, JM
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (04) : 363 - 365
  • [27] TAP1 AND TAP2 POLYMORPHISMS IN HEPATOTOXICITY INDUCED BY AMOXICILLIN-CLAVULANATE (AC DILI)
    Lucena, M. I.
    Stephens, C.
    Garcia, E. M.
    Garcia-Cortes, M.
    Medina-Caliz, I.
    Moreno, I.
    Hallal, H.
    Soriano, G.
    Fernandez, M. C.
    Ruiz-Cabello, F.
    Andrade, R. J.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 29 - 29
  • [28] TAP1, TAP2, LMP2, DMA, and DMB genetic polymorphisms in renal transplantation
    Kobayashi, T
    Yokoyama, I
    Hayashi, S
    Negita, M
    Namil, Y
    Katayama, A
    Nagasaka, T
    Koike, C
    Tachi, Y
    Mei, GL
    Haba, T
    Tominaga, Y
    Naruse, T
    Inoko, H
    Uchida, K
    Takagi, H
    [J]. TRANSPLANTATION PROCEEDINGS, 1998, 30 (01) : 29 - 30
  • [29] Analysis of IL1B, TAP1, TAP2 and IKBL polymorphisms on susceptibility to tuberculosis
    Gomez, LM
    Camargo, JF
    Castiblanco, J
    Ruiz-Narváez, EA
    Cadena, J
    Anaya, JM
    [J]. TISSUE ANTIGENS, 2006, 67 (04): : 290 - 296
  • [30] TAP1 AND TAP2 POLYMORPHISM IN MULTIPLE-SCLEROSIS PATIENTS
    MIDDLETON, D
    MEGAW, G
    CULLEN, C
    HAWKINS, S
    DARKE, C
    SAVAGE, DA
    [J]. HUMAN IMMUNOLOGY, 1994, 40 (02) : 131 - 134